A Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Dose-Escalation, and Expansion Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of AK0610 in Healthy Chinese Adults.
Latest Information Update: 03 Jun 2025
At a glance
- Drugs AK 0610 (Primary)
- Indications Respiratory syncytial virus infections
- Focus Adverse reactions
- Sponsors Ark Biosciences
Most Recent Events
- 03 Jun 2025 New trial record